Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function
- PMID: 40512855
- PMCID: PMC12164974
- DOI: 10.1126/sciadv.adx7845
Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function
Abstract
Regulatory T cell (Treg cell) therapy has been transformed through the use of chimeric antigen receptors (CARs). We previously found that human Treg cells minimally produce IL-10 and have a limited capacity to control innate immunity compared to type 1 regulatory T cells (Tr1 cells). To create "hybrid" CAR Treg cells with Tr1 cell-like properties, we examined whether the PDCD1 locus could be exploited to endow Treg cells with CAR-regulated IL-10 expression. CRISPR-mediated PD1 deletion increased CAR Treg cell activation, and knock-in of IL10 under control of the PD1 promoter resulted in CAR-induced IL-10 secretion. IL10 knock-in improved CAR Treg cell function, as determined by increased suppression of dendritic cells and alloantigen- and islet autoantigen-specific T cells. In vivo, IL10 knock-in CAR Treg cells were stable, safe, and suppressed dendritic cells and xenogeneic graft-versus-host disease. CRISPR-mediated engineering to simultaneously remove an inhibitory signal and enhance a suppressive mechanism is a previously unexplored approach to improve CAR Treg cell potency.
Figures








Similar articles
-
Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive.Eur J Immunol. 2021 Oct;51(10):2522-2530. doi: 10.1002/eji.202048934. Epub 2021 Aug 8. Eur J Immunol. 2021. PMID: 34320225 Free PMC article.
-
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.Front Immunol. 2021 Sep 20;12:686439. doi: 10.3389/fimmu.2021.686439. eCollection 2021. Front Immunol. 2021. PMID: 34616392 Free PMC article.
-
Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells.JCI Insight. 2019 Mar 21;4(6):e123672. doi: 10.1172/jci.insight.123672. eCollection 2019 Mar 21. JCI Insight. 2019. PMID: 30753169 Free PMC article.
-
Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.Front Immunol. 2018 Oct 12;9:2359. doi: 10.3389/fimmu.2018.02359. eCollection 2018. Front Immunol. 2018. PMID: 30369931 Free PMC article. Review.
-
The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology.Front Immunol. 2020 Jul 24;11:1608. doi: 10.3389/fimmu.2020.01608. eCollection 2020. Front Immunol. 2020. PMID: 32793236 Free PMC article. Review.
References
-
- Wardell C. M., Boardman D. A., Levings M. K., Harnessing the biology of regulatory T cells to treat disease. Nat. Rev. Drug Discov. 24, 93–111 (2024). - PubMed
-
- Bluestone J. A., Buckner J. H., Fitch M., Gitelman S. E., Gupta S., Hellerstein M. K., Herold K. C., Lares A., Lee M. R., Li K., Liu W., Long S. A., Masiello L. M., Nguyen V., Putnam A. L., Rieck M., Sayre P. H., Tang Q., Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 7, 315ra189 (2015). - PMC - PubMed
-
- Sawitzki B., Harden P. N., Reinke P., Moreau A., Hutchinson J. A., Game D. S., Tang Q., Guinan E. C., Battaglia M., Burlingham W. J., Roberts I. S. D., Streitz M., Josien R., Böger C. A., Scottà C., Markmann J. F., Hester J. L., Juerchott K., Braudeau C., James B., Contreras-Ruiz L., van der Net J. B., Bergler T., Caldara R., Petchey W., Edinger M., Dupas N., Kapinsky M., Mutzbauer I., Otto N. M., Öllinger R., Hernandez-Fuentes M. P., Issa F., Ahrens N., Meyenberg C., Karitzky S., Kunzendorf U., Knechtle S. J., Grinyó J., Morris P. J., Brent L., Bushell A., Turka L. A., Bluestone J. A., Lechler R. I., Schlitt H. J., Cuturi M. C., Schlickeiser S., Friend P. J., Miloud T., Scheffold A., Secchi A., Crisalli K., Kang S.-M., Hilton R., Banas B., Blancho G., Volk H.-D., Lombardi G., Wood K. J., Geissler E. K., Regulatory cell therapy in kidney transplantation (The ONE Study): A harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet 395, 1627–1639 (2020). - PMC - PubMed
-
- Boardman D., Maher J., Lechler R., Smyth L., Lombardi G., Antigen-specificity using chimeric antigen receptors: The future of regulatory T-cell therapy? Biochem. Soc. Trans. 44, 342–348 (2016). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources